These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26054893)

  • 41. A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.
    Inoue Y; Nakamura A; Kondo Y; Hamano K; Satoh S; Terauchi Y
    J Clin Pharmacol; 2015 Jul; 55(7):831-8. PubMed ID: 25677642
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes.
    Braun D; Konrad D; Lang-Muritano M; Schoenle E
    Pediatr Diabetes; 2008 Aug; 9(4 Pt 2):382-7. PubMed ID: 18331413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K
    Vasc Health Risk Manag; 2010 Jun; 6():399-410. PubMed ID: 20539842
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P
    Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine.
    Fadini GP; de Kreutzenberg SV; Mariano V; Boscaro E; Bertolini F; Mancuso P; Quarna J; Marescotti M; Agostini C; Tiengo A; Avogaro A
    Diabetes Obes Metab; 2011 Aug; 13(8):718-25. PubMed ID: 21410861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2).
    Wheeler MD; Barrientos-Perez M; Lo FS; Liang B; Lunsford A; Thórisdóttir Ó; Zuckerman-Levin N
    Eur J Pediatr; 2018 Oct; 177(10):1497-1503. PubMed ID: 30014302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Achieve control: a pragmatic clinical trial of insulin glargine 300 U/mL versus other basal insulins in insulin-naïve patients with type 2 diabetes.
    Oster G; Sullivan SD; Dalal MR; Kazemi MR; Rojeski M; Wysham CH; Sung J; Johnstone B; Cali AM; Wei LJ; Traylor L; Anhalt H; Hull M; Van Vleet J; Meneghini LF
    Postgrad Med; 2016 Nov; 128(8):731-739. PubMed ID: 27690710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial.
    Fishel Bartal M; Ward C; Blackwell SC; Ashby Cornthwaite JA; Zhang C; Refuerzo JS; Pedroza C; Lee KH; Chauhan SP; Sibai BM
    Am J Obstet Gynecol; 2021 Jul; 225(1):87.e1-87.e10. PubMed ID: 33865836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detemir vs Glargine: Comparison of Inpatient Glycemic Control.
    Capson J; Cade K; Avanesyan A
    J Am Osteopath Assoc; 2019 Feb; 119(2):89-95. PubMed ID: 30688354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P; Kshanti IA; Pramono RB; Langi YA; Dalem-Pemayun TG
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results from the UK cohort of SOLVE: providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.
    Khunti K; Vora J; Davies M
    Prim Care Diabetes; 2014 Apr; 8(1):57-63. PubMed ID: 24378771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
    Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
    J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
    Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
    BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
    DeVries JH; Bain SC; Rodbard HW; Seufert J; D'Alessio D; Thomsen AB; Zychma M; Rosenstock J;
    Diabetes Care; 2012 Jul; 35(7):1446-54. PubMed ID: 22584132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice.
    Rautiainen P; Tirkkonen H; Laatikainen T
    Diabetes Technol Ther; 2018 May; 20(5):363-369. PubMed ID: 29741925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness and safety of different basal insulins in a real-world setting.
    Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
    Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.